These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33398346)

  • 1. Elevated carcinoembryonic antigen predicts rapidly progressive interstitial lung disease in clinically amyopathic dermatomyositis.
    Zhu D; Qiao J; Tang S; Pan Y; Li S; Yang C; Fang H
    Rheumatology (Oxford); 2021 Aug; 60(8):3896-3903. PubMed ID: 33398346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of characteristics and anti-MDA5 antibody distribution and effect between clinically amyopathic dermatomyositis and classic dermatomyositis: a retrospective case-control study.
    Ji Q; Pan W; Zhang D; Hou Y; Wang Z
    Front Immunol; 2023; 14():1237209. PubMed ID: 38098481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
    J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor markers are associated with rapidly progressive interstitial lung disease in adult-dermatomyositis.
    Wang Q; Gao C; Zhang C; Yao M; Liang W; Sun W; Zheng Z
    Clin Rheumatol; 2022 Jun; 41(6):1731-1739. PubMed ID: 35138465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
    Ye Y; Fu Q; Wang R; Guo Q; Bao C
    J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis.
    Zuo Y; Ye L; Liu M; Li S; Liu W; Chen F; Lu X; Gordon P; Wang G; Shu X
    Rheumatology (Oxford); 2020 Oct; 59(10):2829-2837. PubMed ID: 32065646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis.
    Xu Y; Yang CS; Li YJ; Liu XD; Wang JN; Zhao Q; Xiao WG; Yang PT
    Clin Rheumatol; 2016 Jan; 35(1):113-6. PubMed ID: 26660480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis.
    Ishikawa Y; Iwata S; Hanami K; Nawata A; Zhang M; Yamagata K; Hirata S; Sakata K; Todoroki Y; Nakano K; Nakayamada S; Satoh M; Tanaka Y
    Arthritis Res Ther; 2018 Oct; 20(1):240. PubMed ID: 30367666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial lung disease in clinically amyopathic dermatomyositis (CADM) patients: a retrospective study of 41 Chinese Han patients.
    Sun Y; Liu Y; Yan B; Shi G
    Rheumatol Int; 2013 May; 33(5):1295-302. PubMed ID: 23143553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease.
    Nara M; Komatsuda A; Omokawa A; Togashi M; Okuyama S; Sawada K; Wakui H
    Mod Rheumatol; 2014 Jul; 24(4):633-6. PubMed ID: 24252021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study.
    Ye S; Chen XX; Lu XY; Wu MF; Deng Y; Huang WQ; Guo Q; Yang CD; Gu YY; Bao CD; Chen SL
    Clin Rheumatol; 2007 Oct; 26(10):1647-54. PubMed ID: 17308858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease.
    Sato S; Kuwana M; Fujita T; Suzuki Y
    Mod Rheumatol; 2013 May; 23(3):496-502. PubMed ID: 22644102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
    Zuo Y; Ye L; Chen F; Shen Y; Lu X; Wang G; Shu X
    Front Immunol; 2022; 13():845988. PubMed ID: 35320936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.
    Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
    Arthritis Care Res (Hoboken); 2016 May; 68(5):689-94. PubMed ID: 26414240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases.
    Kawasumi H; Katsumata Y; Nishino A; Hirahara S; Kawaguchi Y; Kuwana M; Yamanaka H
    J Rheumatol; 2018 Jul; 45(7):947-955. PubMed ID: 29657141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
    Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T
    Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors for long-term outcome in polymyositis/dermatomyositis-associated interstitial lung diseases.
    Fujisawa T; Hozumi H; Kono M; Enomoto N; Nakamura Y; Inui N; Nakashima R; Imura Y; Mimori T; Suda T
    Respir Investig; 2017 Mar; 55(2):130-137. PubMed ID: 28274528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients.
    Zou J; Guo Q; Chi J; Wu H; Bao C
    Clin Rheumatol; 2015 Apr; 34(4):707-14. PubMed ID: 25609178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Serum B Cell Activating Factor and a Proliferation-inducing Ligand Are Associated with Interstitial Lung Disease in Patients with Juvenile Dermatomyositis.
    Kobayashi N; Kobayashi I; Mori M; Sato S; Iwata N; Shigemura T; Agematsu K; Yokota S; Koike K
    J Rheumatol; 2015 Dec; 42(12):2412-8. PubMed ID: 26472413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum IL8 and mRNA level of CD11b in circulating neutrophils are increased in clinically amyopathic dermatomyositis with active interstitial lung disease.
    Zou J; Chen J; Yan Q; Guo Q; Bao C
    Clin Rheumatol; 2016 Jan; 35(1):117-25. PubMed ID: 26459323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.